Cycle Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CYCLE, and when can generic versions of CYCLE drugs launch?
CYCLE has thirteen approved drugs.
There are four US patents protecting CYCLE drugs.
There are sixteen patent family members on CYCLE drugs in eighteen countries and twenty-four supplementary protection certificates in thirteen countries.
Drugs and US Patents for Cycle
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cycle | CHLORPROMAZINE HYDROCHLORIDE | chlorpromazine hydrochloride | TABLET;ORAL | 085331-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Cycle | CIMETIDINE | cimetidine | TABLET;ORAL | 074361-002 | Dec 23, 1994 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Cycle | RESERPINE | reserpine | TABLET;ORAL | 009859-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Cycle | TASCENSO ODT | fingolimod lauryl sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 214962-002 | Dec 9, 2022 | RX | Yes | Yes | 10,925,829 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Cycle | TASCENSO ODT | fingolimod lauryl sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 214962-001 | Dec 23, 2021 | RX | Yes | No | 10,925,829 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Cycle | QUINIDINE SULFATE | quinidine sulfate | TABLET;ORAL | 083640-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Cycle Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Serbia | 60551 | ⤷ Try a Trial |
China | 107530301 | ⤷ Try a Trial |
Lithuania | 3089740 | ⤷ Try a Trial |
Croatia | P20201135 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2016118515 | ⤷ Try a Trial |
Canada | 2935013 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cycle Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0591275 | 05C0024 | France | ⤷ Try a Trial | PRODUCT NAME: NITISINONE; REGISTRATION NO/DATE: EU/1/04/303/001 20050221 |
1539166 | 2013C/064 | Belgium | ⤷ Try a Trial | PRODUCT NAME: DEXTROMETHORPHANE OU UN SEL, PRCURSEUR DE DERIVE PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRURE DE DEXTROMETORPHANE ET EN PARTICULIER LE BROMHYDRURE DE DEXTROMETROPHANE MONHYDRATE ET QUINIDINE OU UN SEL,....; AUTHORISATION NUMBER AND DATE: EU/1/13/833 20130626 |
1613288 | CR 2011 00023 | Denmark | ⤷ Try a Trial | PRODUCT NAME: FINGOLIMOD, HERUNDER FINGOLIMOD SOM HYDROCHLORID; REG. NO/DATE: EU/1/11/677/001-004 20110317 |
1613288 | PA2011010,C1613288 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: FINGOLIMODUM; REGISTRATION NO/DATE: EU/1/11/677/001, 2011-03-17 EU/1/11/677/002, 2011-03-17 EU/1/11/677/003, 2011-03-17 EU/1/11/677/004 20110317 |
1613288 | 122011100047 | Germany | ⤷ Try a Trial | PRODUCT NAME: FINGOLIMOD ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON; NAT. REGISTRATION NO/DATE: FIRST REGISTRATION: EU EU/1/11/677/001-004 20110317EU/1/11/677/001 EU/1/11/677/002 EU/1/11/677/003 EU/1/11/677/004 20110317 |
0627406 | C300488 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: FINGOLIMOD, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER FINGOLIMOD HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/11/677/001-004 20110317 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.